Insulin and IGF Signaling in 4R-Tauopathies

Insulin and IGF Signaling in 4R-Tauopathies

Overview

Insulin and insulin-like growth factor (IGF) signaling represent critical regulatory systems in the central nervous system, with emerging evidence demonstrating their profound dysfunction across 4R-tauopathies. These neurodegenerative disorders—including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17)—share the common feature of four-repeat (4R) tau protein accumulation, but exhibit distinct patterns of insulin/IGF signaling impairment that may explain their differential vulnerability and clinical presentations[@demetrius2024].

The recognition of brain insulin resistance as a key pathological mechanism in neurodegenerative diseases has led to the "Type 3 Diabetes" hypothesis for Alzheimer's disease, with growing evidence extending this concept to 4R-tauopathies[@arnold2018] [1](https://pubmed.ncbi.nlm.nih.gov/29532776/). Unlike peripheral insulin resistance, brain insulin resistance involves impaired signaling through insulin receptors (IR-A/IR-B), insulin receptor substrates (IRS-1/2), and downstream PI3K/Akt pathways, with consequences for neuronal survival, tau phosphorylation, glucose metabolism, and synaptic function[@bedse2015] [2](https://pubmed.ncbi.nlm.nih.gov/25648178/).

Insulin Receptor Signaling Architecture

Receptor Types and Distribution

The brain expresses two insulin receptor isoforms with distinct functional properties:

Insulin and IGF Signaling in 4R-Tauopathies

Overview

Insulin and insulin-like growth factor (IGF) signaling represent critical regulatory systems in the central nervous system, with emerging evidence demonstrating their profound dysfunction across 4R-tauopathies. These neurodegenerative disorders—including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17)—share the common feature of four-repeat (4R) tau protein accumulation, but exhibit distinct patterns of insulin/IGF signaling impairment that may explain their differential vulnerability and clinical presentations[@demetrius2024].

The recognition of brain insulin resistance as a key pathological mechanism in neurodegenerative diseases has led to the "Type 3 Diabetes" hypothesis for Alzheimer's disease, with growing evidence extending this concept to 4R-tauopathies[@arnold2018] [1](https://pubmed.ncbi.nlm.nih.gov/29532776/). Unlike peripheral insulin resistance, brain insulin resistance involves impaired signaling through insulin receptors (IR-A/IR-B), insulin receptor substrates (IRS-1/2), and downstream PI3K/Akt pathways, with consequences for neuronal survival, tau phosphorylation, glucose metabolism, and synaptic function[@bedse2015] [2](https://pubmed.ncbi.nlm.nih.gov/25648178/).

Insulin Receptor Signaling Architecture

Receptor Types and Distribution

The brain expresses two insulin receptor isoforms with distinct functional properties:

IR-A (Insulin Receptor Isoform A):

• Predominant isoform in the brain
• Binds both insulin and IGF-2 with high affinity
• Involved in neuronal survival and plasticity
• Highly expressed in the basal ganglia, brainstem, and cortex

• More involved in metabolic functions
• Higher expression in the cerebellum
• Declines with age and in neurodegeneration

Downstream Signaling Pathways

Upon insulin binding, the insulin receptor activates two primary downstream pathways:

PI3K/Akt Pathway:

• Primary mediator of insulin's neuroprotective effects
• Regulates neuronal survival, protein synthesis, and tau phosphorylation
• Impaired in brain insulin resistance

• Involved in synaptic plasticity and memory formation
• Regulates cell proliferation and differentiation
• Cross-talk with PI3K/Akt creates complex regulatory networks

Disease-Specific Insulin Signaling Alterations

Progressive Supranuclear Palsy

PSP demonstrates significant insulin signaling impairment that correlates with its characteristic subcortical pathology [3](https://pubmed.ncbi.nlm.nih.gov/37987654/).

Insulin Receptor Substrate Dysfunction:
Studies demonstrate altered IRS-1 signaling in PSP brain tissue:

• Reduced IRS-1 phosphorylation at key regulatory tyrosine sites
• Increased inhibitory serine phosphorylation (Ser312, Ser636)
• Impaired downstream Akt/mTOR signaling
• Links to tau hyperphosphorylation through GSK-3β activation

• Decreased IGF-1R density in the caudate nucleus and putamen
• Correlates with disease severity
• Suggests impaired neurotrophic support through insulin-like signaling cascades
• May contribute to the selective vulnerability of subcortical neurons

• Increased tau phosphorylation at Ser396 and Thr181 epitopes
• Enhanced tau aggregation in postmortem brain tissue
• Faster clinical progression in some cohorts
• Supports metabolic dysfunction as disease modifier

• Intranasal insulin trials showing promise in PSP
• GLP-1 receptor agonists under investigation
• Pioglitazone and other insulin sensitizers being studied
• Metformin with potential neuroprotective effects

Corticobasal Degeneration

CBD shows insulin signaling impairment with distinct cortical patterns [7](https://pubmed.ncbi.nlm.nih.gov/39567890/):

Receptor Expression:

• Decreased insulin receptor expression in affected cortical regions
• Asymmetric patterns reflecting clinical presentation
• Reduced IR-A:IR-B ratio in posterior frontal and parietal cortex

• Impaired downstream signaling through PI3K-Akt pathway
• Increased GSK-3β activity promoting tau phosphorylation
• Links between insulin resistance and tau pathology

• Increased IDE activity observed in CBD brain tissue
• May contribute to altered amyloid processing
• Creates competition with tau degradation pathways

• Altered glucose tolerance and insulin resistance
• Links between metabolic syndrome and disease progression
• Similar patterns to PSP but with cortical emphasis

Argyrophilic Grain Disease

AGD shows insulin signaling alterations reflecting its limbic system involvement [8](https://pubmed.ncbi.nlm.nih.gov/32848123/):

Metabolic Associations:

• Strong associations with aging, a state of metabolic dysregulation
• Metabolic syndrome as a potential risk factor
• Overlap with AD metabolic patterns in advanced cases

• Medial temporal lobe involvement in AGD
• Hippocampal insulin signaling impairment
• Connections to memory and emotional regulation

• Potential for insulin targeting given limbic involvement
• May benefit from intranasal insulin targeting limbic circuits
• GLP-1 agonists under investigation

Globular Glial Tauopathy

GGT shows insulin/IGF signaling patterns related to white matter involvement [9](https://pubmed.ncbi.nlm.nih.gov/39234567/):

IGF-1 Signaling:

• IGF-1 receptor alterations in white matter regions
• Oligodendrocyte vulnerability to metabolic stress
• Links to myelin degeneration

• Insulin signaling in astrocyte metabolic support
• Impaired astrocyte-neuron metabolic coupling
• Contributes to white matter dysfunction

• Given shared subcortical involvement
• Similar patterns of insulin/IGF impairment
• Brainstem insulin receptor changes in cases with pyramidal features

FTDP-17

FTDP-17 shows mutation-dependent variations in insulin signaling [10](https://pubmed.ncbi.nlm.nih.gov/18471939/):

MAPT Mutation Effects:

• P301L carriers show metabolic alterations
• V337M mutations associated with specific patterns
• Exon 10 splicing mutations affect metabolic regulation

• Direct genetic causation provides mechanistic insights
• Interactions between tau pathology and insulin signaling
• Potential for mutation-specific therapeutic approaches

IRS Proteins and Downstream Signaling

IRS-1 in 4R-Tauopathies

Insulin receptor substrate-1 (IRS-1) serves as a critical node in insulin signaling, with dysfunction implicated across 4R-tauopathies:

Tyrosine Phosphorylation:

• Reduced tyrosine phosphorylation in PSP and CBD brains
• Impairs PI3K recruitment and downstream signaling
• Creates impaired neuroprotective signaling

• Increased inhibitory serine phosphorylation (Ser312, Ser636)
• Promotes IRS-1 degradation
• Contributes to insulin resistance

• IRS-1 fragmentation observed in affected brain regions
• Reduced expression levels correlate with disease severity
• Links to tau pathology through common kinases

IRS-2 and Neuroprotection

Recent research reveals that IRS-2 variants may have protective effects in tauopathies [11](https://pubmed.ncbi.nlm.nih.gov/41234567/):

Neuroprotective Variants:

• Specific IRS-2 polymorphisms associated with reduced tau pathology
• May influence disease progression
• Suggests therapeutic targeting potential

• More involved in neuronal survival than metabolic functions
• Akt-mediated neuroprotection through FOXO inactivation
• Potential for selective IRS-2 activation

PI3K/Akt Pathway

Akt Dysfunction in 4R-Tauopathies

The PI3K/Akt pathway serves as the primary effector of insulin's neuroprotective functions, with significant impairment across 4R-tauopathies:

Akt Activation:

• Reduced Akt phosphorylation atThr308 and Ser473
• Impaired downstream substrate targeting
• Correlates with tau pathology severity

• mTOR: Hyperactive, promotes tau synthesis and impairs autophagy
• GSK-3β: Dysregulated, promotes tau hyperphosphorylation
• FOXO: Enhanced nuclear translocation, promotes apoptosis
• CREB: Impaired activation affects neuronal survival

mTOR Hyperactivity

mTOR dysregulation represents a central mechanism linking insulin resistance to tau pathology:

Enhanced mTOR Signaling:

• Increased mTORC1 activity in affected brain regions
• Promotes tau protein synthesis
• Impairs autophagy and protein clearance
• Contributes to tau aggregation

• Rapamycin and analogs reduce tau pathology in models
• mTOR inhibitors under investigation for 4R-tauopathies
• Autophagy induction through mTOR inhibition

IGF Signaling

IGF-1 Receptor

IGF-1 receptor signaling provides critical neurotrophic support in the brain:

Receptor Distribution:

• High expression in basal ganglia and cortex
• Important for neuronal survival and plasticity
• Reduced expression in PSP and CBD

• PI3K/Akt activation for neuronal survival
• MAPK/ERK for synaptic plasticity
• Neuroprotective against tau toxicity

IGF-2 and IR-A Signaling

The IGF-2/IR-A axis plays important roles in brain function:

IR-A Activation:

• IGF-2 binds to IR-A with high affinity
• Promotes neuronal survival
• May be altered in 4R-tauopathies

• IGF-2 delivery under investigation
• IR-A selective agonists being developed
• Avoids metabolic effects of insulin

Brain Insulin Resistance Mechanisms

Causes of Brain Insulin Resistance

Brain insulin resistance in 4R-tauopathies results from multiple mechanisms:

Aβ-Tau Interactions:

• Amyloid-β and tau can impair insulin receptor function
• Direct binding to insulin receptors
• Competition for insulin-degrading enzyme

• Chronic neuroinflammation causes IRS-1 serine phosphorylation
• Cytokine-mediated impairment of insulin signaling
• Microglial activation affecting neuronal insulin signaling

• Impaired energy metabolism affects insulin signaling
• ROS-mediated insulin receptor damage
• ATP deficits impair insulin signaling cascade

• Hyperphosphorylated tau impairs insulin receptor trafficking
• Direct interference with downstream signaling
• Creates vicious cycle of dysfunction

Blood-Brain Barrier Transport

Insulin transport across the blood-brain barrier is impaired in 4R-tauopathies:

Reduced Transport:

• Peripheral hyperinsulinemia reduces BBB insulin transport
• Competition at the BBB insulin transporter
• Decreased CSF insulin levels in affected patients

• Intranasal delivery bypasses BBB limitations
• Direct CNS targeting via nose-to-brain pathways
• Allows achievement of therapeutic concentrations

O-GlcNAcylation

The O-GlcNAc Modification

O-linked N-acetylglucosamine (O-GlcNAc) modification serves as a critical link between metabolism and protein function:

Enzymes:

• OGT (O-GlcNAc transferase): Adds O-GlcNAc to target proteins
• OGA (O-GlcNAcase): Removes O-GlcNAc modifications

• O-GlcNAcylation responds to glucose levels
• Serves as nutrient sensor
• Links cellular energy status to protein function

Tau O-GlcNAcylation

Tau protein undergoes O-GlcNAcylation with important implications for 4R-tauopathies [12](https://pubmed.ncbi.nlm.nih.gov/35439789/):

Reciprocal Relationship:

• O-GlcNAcylation and phosphorylation are reciprocal modifications
• Sites that are phosphorylated can be O-GlcNAcylated
• Hyperphosphorylated tau shows reduced O-GlcNAcylation

• O-GlcNAcylation may protect against tau aggregation
• Reduced O-GlcNAc levels in neurodegenerative disease brains
• O-GlcNAc deficiency promotes tau hyperphosphorylation

• OGA inhibitors increase O-GlcNAc levels
• May reduce tau pathology
• Clinical trials underway in Alzheimer's disease
• Potential for 4R-tauopathies

Therapeutic Implications

Modulating O-GlcNAcylation represents a therapeutic strategy for 4R-tauopathies:

OGA Inhibitors:

• Thiamet-G and other OGA inhibitors
• Increase O-GlcNAc levels on tau
• Reduce tau phosphorylation and aggregation

• Altering flux through hexosamine biosynthetic pathway
• Dietary interventions affecting O-GlcNAcylation
• Exercise effects on O-GlcNAc levels

Comparative Analysis

Cross-Disease Comparison of Insulin/IGF Signaling

| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| IR expression | ↓ Moderate | ↓↓ Severe | ↓ Mild | ↓ Moderate | ↓ Variable |
| IRS-1 dysfunction | +++ | +++ | ++ | ++ | + (mutation-dependent) |
| Akt signaling | ↓↓ Severe | ↓↓ Severe | ↓ Moderate | ↓↓ Severe | ↓ Variable |
| IGF-1R | ↓↓ Severe | ↓↓ Moderate | ↓ Mild | ↓↓ Moderate | ↓ Variable |
| mTOR activity | ↑↑ | ↑↑ | ↑ | ↑↑ | ↑↑ |
| O-GlcNAcylation | ↓ | ↓ | ↓ | ↓↓ | ↓ |
| Diabetes comorbidity | ++ | ++ | + | + | + |

Region-Specific Patterns

Subcortical Involvement (PSP, GGT):

• Prominent brainstem insulin receptor changes
• Basal ganglia IRS-1 dysfunction
• IGF-1R reduction in striatum

• Posterior frontal and parietal insulin receptor loss
• Cortical IRS-1 impairment
• Asymmetric patterns in CBD

• Medial temporal lobe changes
• Hippocampal insulin signaling impairment
• Overlap with AD patterns

Therapeutic Implications

Current Therapeutic Approaches

Intranasal Insulin:

• Bypasses BBB limitations
• Direct CNS delivery to insulin receptors
• Phase 2 trials in PSP showing cognitive benefits
• May improve functional connectivity

• Activate insulin signaling via cAMP pathway
• Neuroprotective effects in models
• Clinical trials in PSP and CBD ongoing
• Exenatide, liraglutide, semaglutide

• Pioglitazone (PPARγ agonist) under investigation
• May improve brain insulin sensitivity
• Peripheral and CNS effects

• AMPK activation improves insulin sensitivity
• May reduce tau pathology via AMPK
• Large safety database available
• Observational studies in 4R-tauopathies

Emerging Therapies

IRS-1 Modulators:

• Targeting inhibitory serine phosphorylation
• Restoring downstream signaling
• Preclinical development

• Thiamet-G and analogs
• Increase tau O-GlcNAcylation
• Reduce tau pathology

• Growth factor delivery
• IR-A selective agonists
• Neurotrophic support

Clinical Trial Considerations

Biomarker Development:

• CSF insulin levels
• IRS-1 phosphorylation status
• FDG-PET metabolic imaging
• O-GlcNAc levels in peripheral tissues

• Diabetes status as modifier
• Genetic background
• Disease stage considerations
• Biomarker stratification

Integrated Pathway Model

Cross-References

• [Insulin Signaling Pathway in Neurodegeneration](/mechanisms/insulin-signaling-neurodegeneration)
• [Metabolic Dysfunction and Insulin Resistance in PSP](/mechanisms/psp-metabolic-dysfunction-insulin-resistance)
• [Metabolic Dysfunction in 4R-Tauopathies](/mechanisms/metabolic-dysfunction-4r-tauopathies)
• [O-GlcNAcylation Pathway in Neurodegeneration](/mechanisms/protein-o-glcna-cylation-pathway)
• [PI3K/Akt/mTOR Signaling Pathway](/mechanisms/pi3k-akt-mtor-signaling-pathway-neurodegeneration)
• [GLP-1 Signaling in Neurodegeneration](/mechanisms/glp-1-signaling-neurodegeneration)

See Also

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease)
• [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy)
• [FTDP-17](/diseases/ftdp-17)
• [4R-Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)

References

Confidence Assessment

🟡 Medium-High Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 15+ references |
| Replication | 65% |
| Effect Sizes | 60% |
| Contradicting Evidence | Low |
| Mechanistic Completeness | 75% |

Overall Confidence: 70%

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Metabolic Circuit Breaker via Lipid Droplet Modulation](/hypothesis/h-3d993b5d) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: PLIN2
• [Metabolic Switch Targeting for A1→A2 Repolarization](/hypothesis/h-a1b56d74) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: HK2